Page 2 - Jubilant Life Sciences

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir

According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries

Jubilant Life, Cipla rally up to 6% on inking pact with Gilead Sciences

According to the statements issued by Jubilant Life and Cipla, both the firms will have the right to register, manufacture and sell Gilead's Remdesivir drug in 127 countries including India

Jubilant Life inks non-exclusive licensing pact with Gilead for Remdesivir

The drug, which is an injectable, got emergency approval from the US drug regulator recently.

Nifty outlook and top trading ideas by Jay Anand Thakkar of Anand Rathi

The Nifty has provided a sell crossover on its hourly charts and with that, the index seems to have reversed the overall trend in the short term.

Jubilant Life Q2 net rises 19%; board approves ingredient business demerger

Drug firm Jubilant Life Sciences on Friday reported a 18.88 per cent rise in consolidated net profit at Rs 249.39 crore for the quarter ended September 30, 2019. The company said its board has also approved demerger of the Life Science Ingredients business. Jubilant Life had posted a net profit of Rs 209.77 crore in the corresponding July-September period of the previous fiscal, it said in a filing to the BSE. Consolidated total revenue from operations stood at Rs 2,265.93 crore for the quarter under consideration as against Rs 2,269.49 crore in the same period a year ago. "We witnessed steady performance in revenue and improvement in operating profits in Q2'FY20 both on a YoY basis and sequentially," Jubilant Life Sciences Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said. The board of the company has approved the recommendations of a committee constituted to consider the option of reorganising the businesses of the company. The board has given go-ahead to ...

Jubilant Life Sciences posts net loss of Rs 100.65 crore in March quarter

Jubilant Life Sciences Friday reported a net loss of Rs 100.65 crore in the fourth quarter ended March 31, 2019 on account of a one time loan settlement with International Finance Corporation (IFC). The company had posted a consolidated net profit of Rs 152.40 crore in the year-ago period, Jubilant Life Sciences said in a regulatory filing. Jubilant Life Sciences said its bottomline in the quarter was hit by a one time loan settlement with IFC, that resulted in an exceptional item of Rs 234.76 crore for the quarter ended March 31. Its consolidated total income during the fourth quarter ended March 31, 2019, stood at Rs 2,379 crore as compared to Rs 2,274.87 crore last year. Jubilant Life Sciences total expenses was higher at Rs 2,184.22 crore as compared to 2,048.31 crore in the year-ago quarter. "The company witnessed healthy performance during the quarter, which was offset by certain one-time charges," Jubilant Life Sciences Chairman Shyam S Bhartia and Co-Chairman & Managing ..

Jubilant Life Sciences arm recalls 12,960 bottles of esophagitis drug in US

Reason for recall is "Discoloration: expansion of an earlier recall due to the presence of dark brown discoloration on the edges of the tablets"

Jubilant Life falls 6% as USFDA recommends action on failing inspection

The stock dipped 6% to Rs 742 on the BSE after the US health regulator recommended a regulatory or administrative action after the inspection of the drug firm's Roorkee manufacturing facility.

USFDA recommends regulatory action on Jubilant Life's Roorkee plant

The FDA has classified the inspection of the Roorkee plant as 'Official Action Indicated'

Jubilant Life Sciences' subsidiary to acquire Inipharm for around $28.5 mn

The company's wholly-owned subsidiary has entered into a stock purchase agreement to acquire 534,194 shares of common stock of biotechnology firm Inipharm Inc USA

Jubilant Life Sciences falls 11% after block deals

The stock slipped 11% to Rs 883 on the NSE in intra-day trade on Friday after a more than seven per cent of the total equity of pharmaceutical company changed hands on the NSE and BSE till noon deal.

Jubilant Life gains on ANDA approval for generic drug

The stock was up 3.4% at Rs 961 in intra-day trade, extending its past two days 3% gain on BSE.

Q3 performance: Multiple growth triggers for Jubilant Life Sciences

Further gains for stock will depend on listing of subsidiary, debt reduction

Jubilant Life Sciences Q3 net surges 80% to Rs 2.12 bn on robust sales

The company continues to reduce debt levels through internal cash generation for a strong balance sheet

Jubilant Life Sciences zooms 15% on strong Q3 results

The stock hit a record high of Rs 931, up 15% on BSE after the pharmaceutical company reported a strong 78% year on year jump in consolidated net profit at Rs 2.13 billion in Q3FY18.

Jubilant Life receives green nod for Rs 2.5-bn greenfield pesticide project

The company has total 20 hectares of area within the Bharuch SEZ, which is operated by Jubilant Infrastructure Ltd

Jubilant Life Sciences up 5% on talk of green panel for pesticide project

The stock of an integrated global pharmaceutical and life sciences company has rallied 14% in past three trading sessions.

Green panel nod to Jubilant Life's Rs 250-cr pesticide project in Gujarat

Proposed unit to be set up in Bharuch district

Jubilant Life Sciences Q1 net down 12% to Rs 143 crore

Drug firm Jubilant Life Sciences today reported a 12.32 per cent dip in its consolidated net profit to Rs 143.71 crore for the quarter ended on June 30, 2017. The company had posted a net profit of Rs 163.92 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a filing to BSE. Consolidated revenue from operations of the company however rose to Rs 1,596.05 crore for the quarter under consideration as against Rs 1,453.92 crore for the same period year ago, it said. "We have started FY 18 on a steady note, with our pharma segment recording its highest ever revenues during the quarter despite margin contraction in the US generics business", Jubilant Life Sciences Chairman Shyam S Bhartia and Co- Chairman & MD Hari S Bhartia said on the results. The company continues to focus on operating cash generation to reduce its debt levels and strengthen the balance sheet, they added. Shares of Jubilant Life Sciences today closed at

Jubilant Life shares jump 7% as Q4 net profits zooms 14-fold

The company's market valuation went up by Rs 713 crore to Rs 11,516.03 crore